Drugmaker Cipla registered a profit after tax at ₹295 crore during the three months ended June 30, 2014. Its profit after tax in the period last year was ₹485 crore. The company said its performance was not comparable in the two quarters, as this year’s figures included results of Cipla’s subsidiaries from the date they had become a subsidiary of the company.

The company’s net sales in the period under review stood at ₹2,647 crore, as compared to ₹2331 crore in the same period last year. Cipla’s domestic sales stood at ₹1,289 crore in the quarter, as compared to ₹1102 crore last year. The growth was on the back of sales in the respiratory, anti-infective and cardiac segments, it said.

Export of finished medicine forms grew to ₹1218 crore during Q1 FY1415 from ₹1081 crore in the same period last year. The company’s export of active pharmaceutical ingredients marginally declined to ₹140 crore during the quarter under review, from ₹148 crore last year.

Related Topics